News
VNDA
7.26
+1.40%
0.10
Vanda files Form 3 for Senior VP, Medical Director Christos Polymeropoulos
PUBT · 17h ago
Vanda VP, Chief People Officer Scott Laverne Howell files initial beneficial ownership statement
PUBT · 17h ago
Geron appoints Timothy Williams as chief legal officer
TipRanks · 1d ago
Geron names Timothy Williams chief legal officer, corporate secretary
PUBT · 1d ago
Weekly Report: what happened at VNDA last week (0406-0410)?
Weekly Report · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-Zscaler, Carlyle, Weight Watchers
Reuters · 4d ago
Vanda Urges FDA To Withdraw Proposal Extending Drug Review Timelines
NASDAQ · 4d ago
BUZZ-Vanda urges FDA to drop proposal for extending drug review timelines; shares down
Reuters · 4d ago
Vanda calls on FDA to remove proposal extending drug review timelines
TipRanks · 4d ago
Vanda Pharma Highlights Legislative Proposal Contained In FDA's FY 2027 Congressional Budget Justification; Proposal Will Eliminate Simple Statutory Requirement That FDA Must Review NDA Within 180 Days Of Filing
Benzinga · 4d ago
Vanda urges FDA to drop proposal extending statutory drug review timelines
Reuters · 4d ago
VANDA PHARMACEUTICALS INC - PROPOSAL WOULD ELIMINATE FDA 180-DAY NDA REVIEW REQUIREMENT
Reuters · 4d ago
Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines
PR Newswire · 4d ago
Vanda Pharmaceuticals: Undervalued GLP-1 Adjunct Opportunity Driven by Tradipitant’s Pivotal Thetis Trial
TipRanks · 5d ago
Vanda Pharmaceuticals Announces Initiation Of The Thetis Study, A Clinical Trial Of NEREUS For The Prevention Of Vomiting Induced By GLP-1 Receptor Agonists; Topline Results From Thetis Study Expected By Q4 2026; Phase 2 Study Succeeded And Met Its Primary Endpoint
Benzinga · 5d ago
Vanda Pharmaceuticals initiates trial of tradipitant in GLP-1-caused vomiting
TipRanks · 5d ago
Vanda starts Thetis trial of NEREUS to curb GLP-1 therapy vomiting
Reuters · 5d ago
VANDA PHARMACEUTICALS INC: PHASE 2 STUDY SUCCEEDED AND MET ITS PRIMARY ENDPOINT
Reuters · 5d ago
Weekly Report: what happened at VNDA last week (0330-0403)?
Weekly Report · 04/06 09:15
Vanda Announces Resignation of Senior Legal Executive
TipRanks · 04/02 22:04
More
Webull provides a variety of real-time VNDA stock news. You can receive the latest news about Vanda Pharma through multiple platforms. This information may help you make smarter investment decisions.
About VNDA
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.